TABLE 1.
Demographics and baseline characteristics.
| Items | Sacubitril/valsartan | Amlodipine | p value a | ||
|---|---|---|---|---|---|
| (N = 179) | (N = 176) | ||||
| Gender—n (%) | 0.646 | ||||
| Male | 136 | (76.0) | 130 | (73.9) | |
| Female | 43 | (24.0) | 46 | (26.1) | |
| Age—years | 0.693 | ||||
| n | 179 | 176 | |||
| Mean (SD) | 58.4 | (9.1) | 58.0 | (8.7) | |
| Median (Q1, Q3) | 59.0 | (53.0, 64.0) | 58.5 | (51.0, 64.0) | |
| Age—n (%) | 0.968 | ||||
| < 65 years | 138 | (77.1) | 136 | (77.3) | |
| ≥ 65 | 41 | (22.9) | 40 | (22.7) | |
| Age—n (%) | 0.818 | ||||
| < 75 years | 171 | (95.5) | 169 | (96.0) | |
| ≥ 75 | 8 | (4.5) | 7 | (4.0) | |
| BMI (kg/m2) | 0.419 | ||||
| n | 179 | 176 | |||
| Mean (SD) | 25.86 | (4.00) | 25.53 | (3.68) | |
| Median (Q1, Q3) | 25.38 | (23.05, 28.03) | 24.90 | (23.11, 27.59) | |
| BMI (kg/m2)—n (%) | 0.125 | ||||
| < 25 | 79 | (44.1) | 92 | (52.3) | |
| ≥ 25 | 100 | (55.9) | 84 | (47.7) | |
| Dipper/Non‐dipper—n (%) | 0.062 | ||||
| Dipper | 114 | (63.7) | 95 | (54.0) | |
| Non‐dipper | 64 | (35.8) | 80 | (45.5) | |
| Unknown | 1 | (0.6) | 1 | (0.6) | |
| 24‐h SBP (mmHg) | 0.196 | ||||
| n | 179 | 176 | |||
| Mean (SD) | 152.2 | (13.5) | 154.2 | (16.1) | |
| Median (Q1, Q3) | 151.1 | (142.7, 159.2) | 152.1 | (144.0, 163.0) | |
| 24‐h DBP (mmHg) | 0.461 | ||||
| n | 179 | 176 | |||
| Mean (SD) | 96.6 | (9.2) | 97.4 | (10.0) | |
| Median (Q1, Q3) | 96.5 | (89.9, 103.0) | 97.1 | (91.2, 103.9) | |
| Office SBP (mmHg) | 0.676 | ||||
| n | 179 | 176 | |||
| Mean (SD) | 154.3 | (13.6) | 154.9 | (13.0) | |
| Median (Q1, Q3) | 153.0 | (147.0, 163.0) | 154.0 | (147.0, 162.0) | |
| Office DBP (mmHg) | 0.893 | ||||
| n | 179 | 176 | |||
| Mean (SD) | 95.0 | (10.1) | 95.2 | (10.6) | |
| Median (Q1, Q3) | 95.0 | (88.0, 103.0) | 95.5 | (89.0, 102.5) | |
| Classification of blood pressure levels at randomization—n (%) | 0.788 | ||||
| Grade 1 b | 87 | (48.6) | 83 | (47.2) | |
| Grade 2 c | 71 | (39.7) | 72 | (40.9) | |
| Other | 21 | (11.7) | 21 | (11.9) | |
| History of antihypertensive treatment—n (%) | 0.490 | ||||
| No | 47 | (26.3) | 52 | (29.5) | |
| Yes | 132 | (73.7) | 124 | (70.5) | |
| Unknown | 0 | (0.0) | 0 | (0.0) | |
| Duration of hypertension (days) | 0.792 | ||||
| n | 179 | 176 | |||
| Mean (SD) | 1632.1 | (2334.4) | 1564.6 | (2484.6) | |
| Median (Q1, Q3) | 761.0 | (1.0, 1927.0) | 437.5 | (1.0, 1992.0) | |
| eGFR (mL/min/1.73 m2) | 0.223 | ||||
| n | 179 | 176 | |||
| Mean (SD) | 71.362 | (12.145) | 73.191 | (15.844) | |
| Median (Q1, Q3) | 70.650 | (62.440, 78.000) | 70.535 | (63.420, 81.975) | |
| eGFR (mL/min/1.73 m2)—n (%) | 0.844 | ||||
| < 60 | 34 | (19.0) | 32 | (18.2) | |
| ≥ 60 | 145 | (81.0) | 144 | (81.8) | |
| UACR (mg/gCr) | 0.567 | ||||
| n | 178 | 175 | |||
| Mean (SD) | 41.66 | (125.14) | 51.52 | (191.45) | |
| Median (Q1, Q3) | 12.80 | (6.70, 25.60) | 11.70 | (7.20, 24.30) | |
| UACR (mg/gCr)—n (%) | 0.554 | ||||
| < 30 | 141 | (78.8) | 143 | (81.3) | |
| ≥ 30 | 37 | (20.7) | 32 | (18.2) | |
| Unknown | 1 | (0.6) | 1 | (0.6) | |
| History of illness | NA | ||||
| Cerebrovascular accident | 0 | (0.0) | 0 | (0.0) | |
| Cardiac failure | 0 | (0.0) | 0 | (0.0) | |
| Myocardial infarction | 0 | (0.0) | 0 | (0.0) | |
| Atrial fibrillation | 0 | (0.0) | 0 | (0.0) | |
| Diabetes mellitus | 1 | (0.6) | 1 | (0.6) | |
| Dyslipidemia | 18 | (10.1) | 26 | (14.8) | |
| Renal impairment | 1 | (0.6) | 2 | (1.1) | |
| Hyperuricemia | 15 | (8.4) | 25 | (14.2) | |
| Peripheral arterial disease | 0 | (0.0) | 0 | (0.0) | |
| Coronary artery disease other than myocardial infarction | 1 | (0.6) | 0 | (0.0) | |
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; NA, not applicable; Q1, first quartile; Q3, third quartile; SBP, systolic blood pressure; SD, standard deviation; UACR, urine albumin‐to‐creatinine ratio.
a
Chi‐squared test for categorical variables and independent t‐test for continuous variables.
b
office SBP 140–159 mmHg and/or office DBP 90–99 mmHg.
c
office SBP 160–179 mmHg and/or office DBP 100–109 mmHg.